- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06838676
확산 고유 폰틴 신경 교종 및 H3K27 변경 고급 신경 교종의 치료를위한 ACT001
확산 된 고유 폰틴 신경 교종 및 H3K27 개정 고급 신경 교종을 가진 어린이 및 청소년에서 ACT001의 2 상 시험
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
연구 개요
상세 설명
Patients will be enrolled on either Cohort A for newly diagnosed DIPG or on Cohort B [ENROLLMENT PAUSED] for those with progressive / refractory DIPG or progressive / recurrent / refractory H3K27-altered HGG. Each cohort will receive ACT001 at 875 mg/m2 orally BID for 28 days (1 cycle of treatment), up to a maximum dose of 1700 mg BID. If patients are experiencing clinical benefit from study therapy, they will continue to receive ACT001 in repeat 28-day cycles for up to 26 cycles (approximately 2 years) or until disease progression, whichever occurs first. Continuation of treatment beyond 26 cycles may be considered if patients are receiving clinical benefit from the study, at the discretion of the sponsor and treating physician.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Kelsey H Troyer, PhD
- 전화번호: 16147223284
- 이메일: kelsey.troyer@nationwidechildrens.org
연구 장소
-
-
Grafton
-
Auckland, Grafton, 뉴질랜드, 1023
- 아직 모집하지 않음
- Starship Children's Hospital
-
연락하다:
- Sarah Hunter, MB ChB
- 전화번호: +64 9 367 0000
- 이메일: SHunter@adhb.govt.nz
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, 독일, 69120
- 아직 모집하지 않음
- Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)
-
연락하다:
- Olaf Witt, MD
- 전화번호: 49 6221 42 3570
- 이메일: o.witt@kitz-heidelberg.de
-
-
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
연락하다:
- Holly Lindsay, MD
- 전화번호: 720-777-6740
- 이메일: holly.lindsay@childrenscolorado.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Children's National Medical Center
-
연락하다:
- Eugene Hwang, MD
- 전화번호: 202-476-5046
- 이메일: ehwang@childrensnational.org
-
-
Florida
-
Miami, Florida, 미국, 33155
- 아직 모집하지 않음
- Nicklaus Children's Hospital
-
연락하다:
- Ziad Khatib, MD
- 전화번호: 305-662-8360
- 이메일: ziad.khatib@nicklaushealth.org
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 아직 모집하지 않음
- Emory University/Children's Healthcare of Atlanta
-
연락하다:
- Tobey MacDonald, MD
- 전화번호: 404-785-1112
- 이메일: tobey.macdonald@emory.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- C.S. Mott Children's Hospital
-
연락하다:
- Santhosh Upadhyaya, MBBS
- 전화번호: 734-647-8902
- 이메일: saupadhy@med.umich.edu
-
연락하다:
- Carl Koschmann, MD
- 전화번호: 734-647-8902
- 이메일: ckoschma@med.umich.edu
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 아직 모집하지 않음
- St. Louis Children's Hospital
-
연락하다:
- Eric Thompson, MD
- 전화번호: 314-454-2810
- 이메일: t.eric@wustl.edu
-
연락하다:
- Mohamed Abdelbaki, MD
- 이메일: mohameda@wustl.edu
-
-
North Carolina
-
Durham, North Carolina, 미국, 27708
- 아직 모집하지 않음
- Duke University Medical Center
-
연락하다:
- Daniel Landi, MD
- 전화번호: 919-684-2410
- 이메일: daniel.landi@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital
-
연락하다:
- Peter de Blank, MD
- 전화번호: 513-517-2068
- 이메일: Peter.deBlank@cchmc.org
-
Columbus, Ohio, 미국, 43235
- 모병
- Nationwide Children's Hospital
-
연락하다:
- Sara Khan, MD
- 전화번호: 614-722-5758
- 이메일: Sara.Khan@nationwidechildrens.org
-
-
Pennsylvania
-
Philidelphia, Pennsylvania, 미국, 19104
- 아직 모집하지 않음
- Children's Hospital of Philidelphia
-
연락하다:
- MIchael J Fisher, MD
- 전화번호: 215-590-5188
- 이메일: fisherm@email.chop.edu
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- Texas Children's Hospital
-
연락하다:
- Patricia Baxter, MD
- 전화번호: 832-824-4681
- 이메일: pabaxter@txch.org
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
연락하다:
- Erin Crotty, MD
- 전화번호: 206-987-2106
- 이메일: erin.crotty@seattlechildrens.org
-
-
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G1X8
- 모병
- The Hospital for Sick Children (SickKids)
-
연락하다:
- Anirban Das, MD
- 전화번호: 429907 416-813-7654
- 이메일: anirban.das@sickkids.ca
-
-
Quebec
-
Montreal, Quebec, 캐나다, H4A3J1
- 아직 모집하지 않음
- Montreal Children's Hospital
-
연락하다:
- Genevieve Legault, MD
- 전화번호: 60497 514-412-4400
- 이메일: Genevieve.Legault4@mcgill.ca
-
-
-
-
New South Wales
-
Randwick, New South Wales, 호주, 2031
- 모병
- Sydney Children's Hospital
-
연락하다:
- David Ziegler, MBBS, BSc, MD, PhD, FRACP
- 전화번호: 612 9382 1730
- 이메일: d.ziegler@unsw.edu.au
-
-
Queensland
-
South Brisbane, Queensland, 호주, 4101
- 아직 모집하지 않음
- Queensland Children's Hospital
-
연락하다:
- Tim Hassall, MBBS
- 전화번호: 61 7 3068 3593
- 이메일: tim.hassall@health.qld.gov.au
-
-
Victoria
-
Melbourne, Victoria, 호주, 3052
- 아직 모집하지 않음
- Royal Children's Hospital
-
연락하다:
- David Eisenstat, MD
- 이메일: david.eisenstat@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, 호주, 6000
- 아직 모집하지 않음
- Perth Children's Hospital
-
연락하다:
- Nick Gottardo, MBChB, FRACP, PhD
- 전화번호: 618 6456 0241
- 이메일: nick.gottardo@health.wa.gov.au
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollment.
-
Diagnosis:
-
Cohort A: Newly Diagnosed DIPG
-
Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons) with or without biopsy and have completed radiation therapy (RT) within 28 to 35 calendar day prior to start of therapy.
-
Patients must have started RT <42 calendar days from radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery, whichever is later.
- If a biopsy was performed, the date of surgical biopsy will be considered the date of definitive diagnostic surgery; if a patient underwent two upfront surgeries [e.g., biopsy then debulking], this is the date of the second surgery)
-
-
Cohort B [ENROLLMENT PAUSED]: progressive/recurrent DIPG or H3K27-altered HGG OR refractory disease
- Patients with DIPG (no biopsy required), pathologically-confirmed (at diagnosis or recurrence) H3K27-altered DIPG, or extra-pontine H3K27-alteredHGG who have progressive/recurrent or refractory disease
- Progressive/recurrent: patients who have progressive or recurrent disease following frontline treatment must have included at least focal RT. New lesions since completion of frontline RT qualify as progressive disease.
- Refractory disease is defined as: Presence of persistent, measurable, abnormality on conventional MRI that is further distinguished by histology or advanced imaging, OR as determined by the treating physician and discussed with the Study Chair(s) prior to enrollment.
- Patients with H3K27-altered spinal HGG are eligible.
- Patients with metastatic disease are eligible.
-
-
Disease Status
- Cohort A: patients may have any disease status but must have completed initial radiation therapy (RT) before enrollment.
- Cohort B: Patients must have measurable disease assessable by MRI. Patients may have extra neuronal disease.
-
Performance Level: Karnofsky Performance Scale score ≥ 50% for patients > 16 years of age and Lansky Performance Scale score > 50% for patients ≤ 16 years of age (applies to all patients) Note: Patients who are unable to walk because of paralysis, but who are capable of using a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
Prior anti-cancer therapy:
- For Cohort A ONLY:
- Surgery, radiation (focal to disease) and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy) are permissible. Temozolomide administered concurrently with RT is permissible. Bevacizumab use is permitted given the last dose was administered >/= 21 days prior to enrollment. No other prior anticancer therapy for DIPG will be allowed.
- Patients must enroll and start treatment on study between 28 and 35 calendar days post-completion of RT.
- Patients must have started RT <42 calendar days of initial diagnosis (defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries [e.g., biopsy then resection or debulking], this is the date of the second surgery).
- Radiotherapy must have been administered at standard dose of 54 Gy for DIPG patients. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair to confirm eligibility prior to study enrollment.
- For Cohort B ONLY: Patients must have fully recovered from the acute treatment related toxicities (defined as </= Grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy, radiotherapy, or any other treatment modality prior to entering on this study, with the exception of alopecia.
Notes to the above for Cohort B: Patients with chronic Grade 2 toxicities may be eligible per discretion of the Investigator and Sponsor (e.g., Grade 2 chemotherapy-induced neuropathy). Grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible - defined as having been present and stable for > 6 months (such as ifosfamide-related proteinuria) may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the Investigator and Sponsor.)
The wash out period between the prior anti-cancer chemotherapy, and enrollment must be:
-
Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
-
Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.
-
Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.
-
Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
-
Monoclonal antibodies: > 21 days must have elapsed from the infusion of last dose of antibody
-
Radiation therapy:
-
All Cohort B patients: Patients must have received their last fraction of focal irradiation to new sites of progressive disease > 14 days prior to enrollment.
- Patients who received CSI must have received their last fraction > 3 months prior to enrollment.
-
Progressive/recurrent disease: Patients who received re-irradiation to primary disease must have received their last fraction > 3 months prior to study enrollment.
-
Refractory Disease:
- Patients must have completed frontline RT > 6 months prior to enrollment.
- Patients who received re-irradiation to primary disease must have received their last fraction > 3 months prior to study enrollment.
-
-
Stem Cell Transplant: Patients must be ≥ 3 months since autologous stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study
-
Organ Function Requirements (applies to all patients)
-
Adequate bone marrow function defined as:
- Peripheral absolute neutrophil count (ANC) > 1000/mm³
- Platelet count > 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
-
Adequate renal function defined as:
- Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m² or
- A serum creatinine based on age/gender as follows (Schwartz et al. J. Peds, 106:522, 1985): Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ≥ 16 years 1.7 1.4
-
Adequate liver function defined as:
- total bilirubin must be </=1.5X institutional ULN for age
- AST (serum glutamic-oxaloacetic transaminase [SGOT]) / ALT (serum glutamic-oxaloacetic transaminase [SGPT]) ≤ 2.5 × institutional upper limit of normal
- Serum albumin ≥ 2 g/dL
-
Adequate cardiac function defined as:
- Ejection fraction of ≥ 50% by echocardiogram
- QTc ≤ 450 msec (by Bazett formula)
-
For Cohort B: Adequate neurologic function defined as:
- Patients with seizure disorders may be enrolled if seizures are well- controlled. Well controlled is defined by no increase in seizure frequency in the 7 days prior to enrollment.
- Patients with neurological deficits should have deficits that are stable for at least the 7 days prior to enrollment.
-
-
Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
-
Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement.
Exclusion Criteria:
A patient who meets any of the following exclusion criteria will not be eligible in the study (Applies to both cohorts except where noted below):
-
Cohort A only: Patients with metastatic disease.
-
Concomitant medications:
-
Corticosteroids:
- Cohort A - Patients receiving corticosteroids are eligible regardless of dosing
- Cohort B - Patients receiving corticosteroids who have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are eligible
-
Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible (Refer study inclusion criteria relating to anti-cancer therapies)
- Cohort A - Patients that have received any anti-cancer treatment other than surgery, RT, temozolomide concurrent with RT, and/or previous bevacizumab with appropriate washout period are not eligible.
-
Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.
-
Anticonvulsants should be used as clinically indicated. The use of enzyme inducing anticonvulsants is not permitted
-
LHRH agonist / antagonists are not permitted
-
High Dose Biotin (B7) supplements are not permitted
-
-
Concomitant medications used with caution: selective serotonin reuptake inhibitor (SSRI) such as Lexapro, Fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), and escitalopram should be used with caution.
-
Infection: Patients who currently have an uncontrolled infection (in the opinion of the PI) are not eligible.
-
Patients who have received a prior solid organ transplantation are not eligible.
-
Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are postmenarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
-
Patients of childbearing or child fathering potential must agree to use adequate contraceptive methods (hormonal or barrier method of birth control; abstinence) while being treated on this study and for 3 months after completing therapy. Note: The definition of effective contraception will be based on the judgement of the principal investigator or a designated associate.
-
Patients who are in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
-
Patients who have previously received either ACT001 or parthenolide are not eligible.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort A
Patients with newly-diagnosed DIPG with typical MRI findings |
PO BID at 875 mg/m2 for 28 days |
|
실험적: Cohort B [ENROLLMENT PAUSED]
Patients with progressive/recurrent DIPG or H3K27-altered HGG OR refractory disease |
PO BID at 875 mg/m2 for 28 days |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS) for newly diagnosed DIPG
기간: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
|
To assess the overall survival for newly-diagnosed patients with DIPG treated with RT followed by ACT001. |
From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
|
|
Objective Response Rate (ORR) in Progressive/Refractory/Recurrent HGG after frontline RT
기간: Date on treatment through 30 days following end of protocol treatment
|
To assess the rate of objective response rate (defined as partial response + complete response) in patients who have been treated with at least frontline focal RT and have progressive DIPG or progressive/recurrent/refractory H3K27-altered HGG who are treated with ACT001 |
Date on treatment through 30 days following end of protocol treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival in Progressive/Refractory/Recurrent DIPG and H3K27-altered DIPG
기간: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
|
To estimate the overall survival and duration of disease control for patients who have been treated with at least RT and have progressive DIPG or progressive/recurrent/refractory H3K27-altered HGG who are treated with ACT001 |
From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: David S. Ziegler, MD, FRACP, Sydney Children's Hospitals Network
- 연구 의자: Sara Khan, MD, PhD, FRACP, Nationwide Children's Hospital
- 연구 의자: Peter de Blank, MD, MSCE, Children's Hospital Medical Center, Cincinnati
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CONNECT2110
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .